BT Slingsby, as Managing Director of Catalys Pacific, invests in early-stage life sciences companies at the pre-seed, seed. See contact routes.
BT Slingsby, as Managing Director of Catalys Pacific, invests in early-stage life sciences companies at the pre-seed, seed, and seed+ stages, focusing on novel therapeutics, diagnostics, and vaccines within the healthcare sector. His distinctive thesis centers on transpacific bioventure creation, leveraging partnerships between Japan and North America to transform biotechnology innovation in Japan. Notable portfolio companies he has founded or led include Mineralys Therapeutics, Pathalys Pharma, Kirilys Therapeutics, and Renalys Pharma, which target unmet medical needs like chronic kidney disease and precision oncology. Specific check sizes are not publicly disclosed, though the firm manages funds such as the $14 million Post-POC Fund backed by Japan Investment Corporation.
Details on this investor come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist investors in Tokyo.
Investors like BT Slingsby · Full investor directory · Investor access · Company funding database